What question did this study set out to answer?

To compare the pharmacodynamic and pharmacokinetic profiles, therapeutic advantages, and clinical limitations of traditional anticoagulants with novel direct and indirect agents.

June 1, 2010Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery)

Old Versus New Anticoagulants: Focus on Pharmacology

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

SBSihame BenmiraMayo Clinic Health System ZBZuliana K. Banda VBVish BhattacharyaNational Health Service

Discussion

Member takes

Implication

May favor novel anticoagulants in select patients; extends pharmacological comparisons but leaves definitive outcome trials open.

Key Points

To compare the pharmacodynamic and pharmacokinetic profiles, therapeutic advantages, and clinical limitations of traditional anticoagulants with novel direct and indirect agents.
Comparative pharmacological analysis of established anticoagulants (heparin, low molecular weight heparin, warfarin) versus novel agents (fondaparinux, idraparinux, rivaroxaban, apixaban, dabigatran, ximelagatran).
Review of recent patents targeting improvements in antithrombotic safety, efficacy, and alternative mechanisms of anticoagulation.
Established anticoagulants present major clinical drawbacks, including mandatory routine coagulation monitoring, narrow therapeutic windows, severe adverse risks (hemorrhage, osteoporosis), and lack of oral formulations for heparins.
Novel factor Xa inhibitors and direct thrombin inhibitors demonstrate more predictable pharmacokinetics, oral bioavailability, and favorable safety profiles without requiring continuous laboratory monitoring.

Structured PICO

Intervention

Established anticoagulants (heparin, LMWH, warfarin) and new anticoagulants (fondaparinux, idraparinux, rivaroxaban, apixaban, dabigatran, ximelagatran)

This review highlights the pharmacological advantages of newer direct oral anticoagulants over traditional agents like warfarin and heparin, emphasizing their predictable pharmacokinetics and improved safety profiles.

Cite This Study

Benmira et al. (2010) studied this question.

synapsesocial.com/papers/6a82a90c061372775e6d0bdf https://doi.org/10.2174/157489010791515269

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Old Versus New Anticoagulants: Focus on Pharmacology

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Old Versus New Anticoagulants: Focus on Pharmacology

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider